Pfizer and Ionis Discontinue Vupanorsen in Dyslipidemia; Glooko Acquires xbird; Madrigal Announces Positive Ph3 MAESTRO-NAFLD-1 Topline Results
Three cardiometabolic-related news items have been observed: Pfizer and Ionis announced they are discontinuing vupanorsen development for dyslipidemia following Ph2b topline results; Glooko announced it has acquired xbird; and Madrigal Pharmaceuticals announced positive topline results from its Ph3 MAESTRO-NAFLD-1 resmetirom study and hosted an associated webcast (listen to webcast here; slides). Below, FENIX provides highlights and insights for the respective new items.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.